myrwdРеальная клиническая практика: данные и доказательстваReal-World Data & Evidence2782-3784Publishing House OKI10.37489/2782-3784-myrwd-058LFCMOSmyrwd-80Research ArticleОЦЕНКА ТЕХНОЛОГИЙ ЗДРАВООХРАНЕНИЯHEALTH TECHNOLOGY ASSESSMENTМетоды решения практических вопросов в процессе оценки стоимости биоаналоговApproaches to resolve practical challenges in the context of assessing the price of biosimilar productshttps://orcid.org/0009-0001-2228-8565ВалееваА. Х-М.ValeevaA. H.-M.

Валеева Алтынай Хаджи-Муратовна — ординатор кафедры клинической фармакологии и доказательной медицины

Санкт-Петербург 

Altynai H.-M. Valeeva — Resident of the department of Clinical Pharmacology and Evidence-Based Medicine

St. Petersburg

sovoglazka2000@yandex.ruhttps://orcid.org/0000-0002-8044-9638БарановаМ. И.BaranovaM. I.

Баранова Марина Ивановна — ассистент кафедры клинической фармакологии и доказательной медицины

Санкт-Петербург 

Marina I. Baranova — assistant of the department of Clinical Pharmacology and Evidence-Based Medicine

St. Petersburg

baranova_m_i@mail.ruФГБОУ ВО «Первый Санкт-петербургский государственный медицинский университет имени И. П. Павлова»РоссияPavlov First Saint Petersburg State Medical UniversityRussian Federation202430122024441118Copyright © Валеева А.Х., Баранова М.И., 20252025Валеева А.Х., Баранова М.И.Valeeva A.H., Baranova M.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.myrwd.ru/jour/article/view/80

Биоаналоги сталкиваются со значительными проблемами при оценке их стоимости. Быстрое развитие данного направления фармацевтической индустрии требует переосмысления экономической оценки препаратов и оптимизации регуляторных процедур.

Biosimilars face significant challenges in assessing their value. The rapid development of this area of t he pharmaceutical industry requires a rethinking of the economic evaluation of drugs and optimization of regulatory procedures.

биоаналогиоценка медицинских технологийbiosimilarshealth technology assessmentReferencesColloca L. The Nocebo Effect. Annu Rev Pharmacol Toxicol. 2024 Jan 23;64:171-190. doi: 10.1146/annurev-pharmtox-022723-112425.Colloca L. The Nocebo Effect. Annu Rev Pharmacol Toxicol. 2024 Jan 23;64:171-190. doi: 10.1146/annurev-pharmtox-022723-112425.ГОСТ Р 56044-2014. Национальный стандарт Российской Федерации. Оценка медицинских технологий. Общие положения. М.: Стандартинформ, 2015 годGOST R 56044-2014. National standard of the Russian Federation. Assessment of medical technologies. General provisions. Moscow: Standartinform, 2015].Государственный реестр лекарственных средств от 18 ноября 2024 г. Текст Реестра по состоянию на указанную дату приведен в соответствии с публикацией на сайте http://grls.rosminzdrav.ru/grls.aspxState Register of Medicines dated November 18, 2024. The text of the Register as of the specified date is given in accordance with the publication on the website]Cheson BD, Leonard JP. Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma. N Engl J Med. 2008 Aug 7;359(6):613-26. doi: 10.1056/NEJMra0708875.Cheson BD, Leonard JP. Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma. N Engl J Med. 2008 Aug 7;359(6):613-26. doi: 10.1056/NEJMra0708875.Современное представление о биоаналогах в гематологии и онкологии В.В. Птушкин ФГБУ ФНКЦ ДГОИ им. Дмитрия Рогачева Минздрава России, Москва онкогематология, 1, 2013Modern concept of bioanalogues in hematology and oncology V.V. Ptushkin Federal State Budgetary Institution Federal Scientific Center of Pediatric Hematology and Oncology named after Dmitry Rogachev, Ministry of Health of the Russian Federation, Moscow Oncohematology, 1, 2013].Перечень взаимозаменяемых лекарственных препаратов для медицинского применения в отношении референтных лекарственных препаратов для медицинского применения и воспроизведенных лекарственных препаратов для медицинского применения, в регистрационных досье на которые имеются результаты исследований биоэквивалентности или исследований терапевтической эквивалентности по отношению к референтному лекарственному препарату, сформированы экспертным учреждением (актуальный на 29.06.2020) в целях размещения Минздравом России на своем официальном сайте в сети «Интернет» до 1 июля 2020 годаThe list of interchangeable medicinal products for medical use in relation to reference medicinal products for medical use and generic medicinal products for medical use, in the registration dossiers of which there are results of bioequivalence studies or therapeutic equivalence studies in relation to the reference medicinal product, has been compiled by an expert institution (current as of 06/29/2020) for the purpose of posting by the Ministry of Health of Russia on its official website on the Internet before July 1, 2020].Федеральный закон «Об обращении лекарственных средств» от 12.04.2010 N 61-ФЗ.Federal Law "On the Circulation of Medicines" dated 12.04.2010 N 61-FZ].Совет Евразийской экономической комиссии. Решение от 3 ноября 2016 года N 89 об утверждении Правил проведения исследований биологических лекарственных средств Евразийского экономического союза (с изменениями на июль 2023 года)Council of the Eurasian Economic Commission. Decision of November 3, 2016 N 89 on approval of the Rules for conducting research on biological medicinal products of the Eurasian Economic Union (as amended in July 2023)].Pouillon L, Socha M, Demore B, Thilly N, Abitbol V, Danese S, Peyrin-Biroulet L. The nocebo effect: a clinical challenge in the era of biosimilars. Expert Rev Clin Immunol. 2018 Sep;14(9):739749. doi: 10.1080/1744666X.2018.1512406.Pouillon L, Socha M, Demore B, Thilly N, Abitbol V, Danese S, Peyrin-Biroulet L. The nocebo effect: a clinical challenge in the era of biosimilars. Expert Rev Clin Immunol. 2018 Sep;14(9):739749. doi: 10.1080/1744666X.2018.1512406.Uhrmann MF, Gissel C. PMS7-Loss of QALYs associated with biosimilar discontinuation due to nocebo effect. Value Health. 2018;21(suppl 3):S289.Uhrmann MF, Gissel C. PMS7-Loss of QALYs associated with biosimilar discontinuation due to nocebo effect. Value Health. 2018;21(suppl 3):S289.Huoponen S, Eberl A, Räsänen P, Roine RP, Sipponen T, Arkkila P, Blom M. Health-related quality of life and costs of switching originator infliximab to biosimilar one in treatment of inflammatory bowel disease. Medicine (Baltimore). 2020 Jan;99(2):e18723. doi: 10.1097/MD.0000000000018723.Huoponen S, Eberl A, Räsänen P, Roine RP, Sipponen T, Arkkila P, Blom M. Health-related quality of life and costs of switching originator infliximab to biosimilar one in treatment of inflammatory bowel disease. Medicine (Baltimore). 2020 Jan;99(2):e18723. doi: 10.1097/MD.0000000000018723.Kaplan GG, Ma C, Seow CH, Kroeker KI, Panaccione R. The Argument Against a Biosimilar Switch Policy for Infliximab in Patients with Inflammatory Bowel Disease Living in Alberta. J Can Assoc Gastroenterol. 2020 Oct;3(5):234-242. doi: 10.1093/jcag/gwz044.Kaplan GG, Ma C, Seow CH, Kroeker KI, Panaccione R. The Argument Against a Biosimilar Switch Policy for Infliximab in Patients with Inflammatory Bowel Disease Living in Alberta. J Can Assoc Gastroenterol. 2020 Oct;3(5):234-242. doi: 10.1093/jcag/gwz044.Mathurin K, Castonguay A, Parison D, Rahal Y, Lachaine J, Beauchemin C. PBI10 Economic impact of originator-to-biosimilar non-medical switching on health care resource utilization in rheumatic patients in Quebec, Canada. Value Health. 2021;24(suppl 1): S16Mathurin K, Castonguay A, Parison D, Rahal Y, Lachaine J, Beauchemin C. PBI10 Economic impact of originator-to-biosimilar non-medical switching on health care resource utilization in rheumatic patients in Quebec, Canada. Value Health. 2021;24(suppl 1): S16Silva SSC, Mahesh B, Rajakulenthiran T, Singh R, Amarasena RAB. 1196 a study reviewing the associated factors and cost-evaluation of switching back to originator-etanercept from its biosimilar among patients with rheumatic disorders at a tertiary care centre in United Kingdom. Ann Rheum Dis. 2020;79(suppl 1):1889.Silva SSC, Mahesh B, Rajakulenthiran T, Singh R, Amarasena RAB. 1196 a study reviewing the associated factors and cost-evaluation of switching back to originator-etanercept from its biosimilar among patients with rheumatic disorders at a tertiary care centre in United Kingdom. Ann Rheum Dis. 2020;79(suppl 1):1889.Moorkens E, Broux H, Huys I, Vulto AG, Simoens S. Economic evaluation of biosimilars for reimbursement purposes - what, when, how? J Mark Access Health Policy. 2020 Mar 15;8(1):1739509. doi: 10.1080/20016689.2020.1739509.Moorkens E, Broux H, Huys I, Vulto AG, Simoens S. Economic evaluation of biosimilars for reimbursement purposes - what, when, how? J Mark Access Health Policy. 2020 Mar 15;8(1):1739509. doi: 10.1080/20016689.2020.1739509.Федеральный закон от 21.11.2011 N 323ФЗ (ред. от 08.08.2024, с изм. от 26.09.2024) "Об основах охраны здоровья граждан в Российской Федерации" (с изм. и доп., вступ. в силу с 01.09.2024)Federal Law of 21.11.2011 N 323-FZ (as amended on 08.08.2024, as amended on 26.09.2024) "On the Fundamentals of Health Protection of Citizens in the Russian Federation" (as amended and supplemented, entered into force on 01.09.2024)].Методические рекомендации «Оценка эффективности и безопасности биоподобных (биоаналоговых) препаратов в странах ЕАЭС: эритропоэтин» Москва, 2023Guidelines "Assessment of the effectiveness and safety of biosimilar (bioanalog) drugs in the EAEU countries: erythropoietin" Moscow, 2023].Белоусов Д.Ю. Биоаналоги – насколько они подобны? Качественная клиническая практика. 2006;(2):80-83.Belousov D.Yu. Biosimilar – how similar are they? Good clinical practice. 2006;(2):80-83.].Ascef BO, Lopes ACF, de Soárez PC. Health technology assessment of biosimilars worldwide: a scoping review. Health Res Policy Syst. 2020 Aug 26;18(1):95. doi: 10.1186/s12961-020-00611-y.Ascef BO, Lopes ACF, de Soárez PC. Health technology assessment of biosimilars worldwide: a scoping review. Health Res Policy Syst. 2020 Aug 26;18(1):95. doi: 10.1186/s12961-020-00611-y.Food and Drug Administration. Scientific considerations in demonstrating biosimilarity to a reference product. Washington, DC: U.S. Department of Health and Human Services, Food and Drug Administration; 2019.Food and Drug Administration. Scientific considerations in demonstrating biosimilarity to a reference product. Washington, DC: U.S. Department of Health and Human Services, Food and Drug Administration; 2019.World Health Organization. Guidelines on evaluation of similar biotherapeutic products. Geneva: WHO; 2009.World Health Organization. Guidelines on evaluation of similar biotherapeutic products. Geneva: WHO; 2009.Simoens S. Biosimilar medicines and cost-effectiveness. Clinicoecon Outcomes Res. 2011;3:2936. doi: 10.2147/CEOR.S12494.Simoens S. Biosimilar medicines and cost-effectiveness. Clinicoecon Outcomes Res. 2011;3:2936. doi: 10.2147/CEOR.S12494.Vakil, N., Fanikos, J. Regulatory and Clinical Perspective on Biosimilars: a Comparison of the US and European Experiences. Curr Emerg Hosp Med Rep. 2019;7:111-117. doi: 10.1007/s40138-019-00185-2Vakil, N., Fanikos, J. Regulatory and Clinical Perspective on Biosimilars: a Comparison of the US and European Experiences. Curr Emerg Hosp Med Rep. 2019;7:111-117. doi: 10.1007/s40138-019-00185-2Kirchhoff CF, Wang XM, Conlon HD, Anderson S, Ryan AM, Bose A. Biosimilars: Key regulatory considerations and similarity assessment tools. Biotechnol Bioeng. 2017 Dec;114(12):2696-2705. doi: 10.1002/bit.26438.Kirchhoff CF, Wang XM, Conlon HD, Anderson S, Ryan AM, Bose A. Biosimilars: Key regulatory considerations and similarity assessment tools. Biotechnol Bioeng. 2017 Dec;114(12):2696-2705. doi: 10.1002/bit.26438.Inotai A, Csanadi M, Petrova G, Dimitrova M, Bochenek T, Tesar T, York K, Fuksa L, Kostyuk A, Lorenzovici L, Omelyanovskiy V, Egyed K, Kalo Z. Patient Access, Unmet Medical Need, Expected Benefits, and Concerns Related to the Utilisation of Biosimilars in Eastern European Countries: A Survey of Experts. Biomed Res Int. 2018 Jan 10;2018:9597362. doi: 10.1155/2018/9597362.Inotai A, Csanadi M, Petrova G, Dimitrova M, Bochenek T, Tesar T, York K, Fuksa L, Kostyuk A, Lorenzovici L, Omelyanovskiy V, Egyed K, Kalo Z. Patient Access, Unmet Medical Need, Expected Benefits, and Concerns Related to the Utilisation of Biosimilars in Eastern European Countries: A Survey of Experts. Biomed Res Int. 2018 Jan 10;2018:9597362. doi: 10.1155/2018/9597362.

The authors declare that there are no conflicts of interest present.